摘要
目的 探讨埃索美拉唑联合马来酸伊索拉定治疗非甾体消炎药相关性小肠病变的可行性.方法 将50只SD大鼠完全随机分为5组：埃索美拉唑与马来酸伊索拉定联合治疗组、马来酸伊索拉定治疗组、埃索美拉唑治疗组、模型组与空白对照组,每组10只.治疗组与模型组均给予双氯芬酸钠（15 mg/kg灌胃）造模,对照组给予0.9％氯化钠注射液1 ml灌胃,连用3d,3d后治疗组分别给予埃索美拉唑、马来酸伊索拉定、埃索美拉唑与马来酸伊索拉定联合用药,空白对照组与模型组给予0.9％氯化钠注射液1 ml,7d后处死大鼠,取小肠组织行苏木精—伊红（HE）染色观察病理改变,对各组大鼠行黏膜组织学损伤评分与肠黏膜损伤大体形态评分,并进行比较.用实时定量聚合酶链反应（PCR）检测各组大鼠小肠组织环氧合酶-1、环氧合酶-2的mRNA水平.结果 与空白对照组相比,模型组大鼠小肠黏膜损伤大体形态评分和组织病理评分明显增高,差异有统计学意义[（4.59±0.40）分比（0.00±0.00）分,（4.00±0.08）分比（0.00±0.00）分,P＜0.05].与模型组相比,埃索美拉唑治疗组、马来酸伊索拉定治疗组、埃索美拉唑与马来酸伊索拉定联合治疗组大体形态评分、病理评分明显降低,差异有统计学意义（P＜0.05）.与埃索美拉唑治疗组、马来酸伊索拉定治疗组相比,埃索美拉唑与马来酸伊索拉定联合治疗组大体形态评分和病理评分明显降低,差异有统计学意义[（1.98±0.88）分比（2.80±1.21）、（3.10±1.02）分,（1.67 ±0.98）分比（2.2l±1.01）、（2.18±0.91）分,P＜0.05].与空白对照组相比,模型组小肠、环氧合酶-l mRNA水平明显降低、环氧合酶-2 mRNA水平明显增高,差异有统计学意义（1.09 ±0.40比3.23±0.65、3.50±0.34比0.23 ±0.12,P＜0.05）.与模型组相比,埃索美拉唑治疗组、马来酸伊索拉定治疗组、埃索美拉唑与马来酸伊索拉定联合
Objective To explore the effect of esomeprazole combined with irsogladine on small intestine injury induced by non steroidal anti inflammatory drug （NSAID）.Methods Fifty adult SD rats were randomly divided into control group,model group,irsogladine maleate group,esomeprazole group and irsogladine maleate combined with esomeprazole group （each n =10）.Model group and the three drug groups were administrated with 15 mg/kg diclofenac and control group was administrated with 0.9％ sodium chloride （intragastric administration） for 3 days,and then the related drugs were administrated the three drug groups,and 0.9％ sodium chloride were administrated in control group and model group for 7 days.After 7 days of treatment,the animals were sacrificed,the pathological changes of the small intestine were observed using hematoxylin-eosin stain and the gross morphological and histological injury were scored.The quantitative polymerase chain reaction was used to detect the mRNA level of cyclooxygenase （COX）-1 and COX-2.Results The gross morphological and histopathological injury score of the small intestine were obviously higher in model group compared with those in control group [（4.59 ± 0.40） scores vs （0.00 ± 0.00） scores,（4.00 ± 0.08） scores vs （0.00 ± 0.00） scores] （P ＜ 0.05）,while were obviously lower in irsogladine maleate group,esomeprazole group and irsogladine maleate combined with esomeprazole group compared with in model group [（2.80 ± 1.21）,（3.10 ± 1.02）,（1.98 ± 0.88） scores vs （4.59 ±0.40） scores,（2.21 ±1.01）,（2.18 ±0.91）,（1.67 ±0.98） scores vs （4.00 ±0.08） scores] （P＜ 0.05）,with statistical differences between irsogladine maleate combined with esomeprazole group and irsogladine maleate group,esomeprazole group （P ＜ 0.05）.The COX-1 mRNA was significantly lower and the COX-2 mRNA was significantly higher in model group compared with control group （1.09 ± 0.40 vs 3.23 ± 0.65,3.50 ± 0.34 vs 0.23 ± 0.12）（P ＜ 0.05�
出处
《中国医药》
2015年第5期671-675,共5页
China Medicine
关键词
小肠损伤
非甾体消炎药
埃索美拉唑
马来酸伊索拉定
Small intestinal injury
Non-steroidal anti-inflammatory drug
Esomeprazole
Irsogladine maleate
